Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)

Dateline City: KENILWORTH, N.J. & SEATTLE Collaboration Builds on Merck’s R&D and NanoString’s Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in multiple tumor types. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orNanoString Investor/Media Relations:Leigh Salvo, 415-513-1281 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: N...
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news